Rigel Pharmaceuticals (RIGL) Other Accumulated Expenses (2010 - 2026)
Rigel Pharmaceuticals' quarterly Other Accumulated Expenses came in at $9.7 million in Q1 2026, up 29.99% year-on-year from $7.4 million in Q1 2025, and down 15.63% quarter-over-quarter from $11.5 million in Q4 2025.
Rigel Pharmaceuticals has reported Other Accumulated Expenses for 17 years, with the latest figure at $9.7 million in Q1 2026.
- For the quarter ending Q1 2026, Other Accumulated Expenses rose 29.99% year-over-year to $9.7 million; the trailing twelve-month figure through Mar 2026 stood at $9.7 million (up 29.99% YoY), and the FY2025 full-year result was $11.5 million, down 2.43% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $9.7 million, down from $11.5 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $17.6 million in Q3 2022, with the low at $4.8 million in Q3 2023.
- Average Other Accumulated Expenses over 5 years is $9.0 million, with a median of $8.6 million recorded in 2025.
- Year-over-year, Other Accumulated Expenses surged 201.63% in 2022 and plunged 72.58% in 2023.
- Tracing RIGL's Other Accumulated Expenses over 5 years: stood at $6.5 million in 2022, then declined by 17.75% to $5.3 million in 2023, then soared by 120.3% to $11.8 million in 2024, then fell by 2.43% to $11.5 million in 2025, then fell by 15.63% to $9.7 million in 2026.
- The last three Other Accumulated Expenses figures came in at $9.7 million (Q1 2026), $11.5 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.67 Mn |
| Dec 31, 2025 | 11.47 Mn |
| Sep 30, 2025 | 8.94 Mn |
| Jun 30, 2025 | 8.59 Mn |
| Mar 31, 2025 | 7.44 Mn |
| Dec 31, 2024 | 11.75 Mn |
| Sep 30, 2024 | 9.97 Mn |
| Jun 30, 2024 | 5.93 Mn |
| Mar 31, 2024 | 5.44 Mn |
| Dec 31, 2023 | 5.33 Mn |
| Sep 30, 2023 | 4.83 Mn |
| Jun 30, 2023 | 5.70 Mn |
| Mar 31, 2023 | 5.62 Mn |
| Dec 31, 2022 | 6.49 Mn |
| Sep 30, 2022 | 17.60 Mn |
| Jun 30, 2022 | 11.82 Mn |
| Mar 31, 2022 | 16.51 Mn |
| Dec 31, 2021 | 13.51 Mn |
| Sep 30, 2021 | 13.49 Mn |
| Jun 30, 2021 | 12.36 Mn |
| Mar 31, 2021 | 5.47 Mn |
| Dec 31, 2020 | 11.01 Mn |
| Sep 30, 2020 | 9.04 Mn |
| Jun 30, 2020 | 7.64 Mn |
| Mar 31, 2020 | 6.93 Mn |
| Dec 31, 2019 | 6.72 Mn |
| Sep 30, 2019 | 6.81 Mn |
| Jun 30, 2019 | 4.93 Mn |
| Mar 31, 2019 | 6.76 Mn |
| Dec 31, 2018 | 3.60 Mn |
| Sep 30, 2018 | 3.76 Mn |
| Jun 30, 2018 | 3.09 Mn |
| Mar 31, 2018 | 5.55 Mn |
| Dec 31, 2017 | 3.33 Mn |
| Sep 30, 2017 | 1.52 Mn |
| Jun 30, 2017 | 996,000.00 |
| Mar 31, 2017 | 1.47 Mn |
| Dec 31, 2016 | 1.03 Mn |
| Sep 30, 2016 | 1.04 Mn |
| Jun 30, 2016 | 1.27 Mn |
| Mar 31, 2016 | 847,000.00 |
| Dec 31, 2015 | 1.13 Mn |
| Sep 30, 2015 | 1.24 Mn |
| Jun 30, 2015 | 545,000.00 |
| Mar 31, 2015 | 992,000.00 |
| Dec 31, 2014 | 534,000.00 |
| Sep 30, 2014 | 880,000.00 |
| Jun 30, 2014 | 731,000.00 |
| Mar 31, 2014 | 571,000.00 |
| Dec 31, 2013 | 746,000.00 |
| Sep 30, 2013 | 652,000.00 |
| Jun 30, 2013 | 690,000.00 |
| Mar 31, 2013 | 873,000.00 |
| Dec 31, 2012 | 942,000.00 |
| Sep 30, 2012 | 3.27 Mn |
| Jun 30, 2012 | 3.52 Mn |
| Mar 31, 2012 | 2.77 Mn |
| Dec 31, 2011 | 504,000.00 |
| Sep 30, 2011 | 2.50 Mn |
| Jun 30, 2011 | 2.55 Mn |
| Dec 31, 2010 | 4.36 Mn |